Lukas Biomedical (ROCO:6814) EPS (Basic): NT$-2.05 (TTM As of Dec. 2025)


ROCO:6814 Lukas Biomedical Inc ROCO:6814
65 GF Score
Price NT$25.60
GF Value NT$21.85
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Lukas Biomedical EPS (Basic)?

Lukas Biomedical ROCO:6814 65 EPS (Basic) is NT$-2.05 as of Dec. 2025. GuruFocus rates ROCO:6814 with a GF Score™ of 65/100 and a GF Value™ of NT$21.85 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Lukas Biomedical's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was NT$-1.03. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-2.05.

Lukas Biomedical's EPS (Diluted) for the six months ended in Dec. 2025 was NT$-1.03. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-2.05.

Lukas Biomedical's EPS without NRI for the six months ended in Dec. 2025 was NT$-1.03. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -2.05.

During the past 3 years, the average EPS without NRI Growth Rate was -14.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -33.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 8 years, Lukas Biomedical's highest 3-Year average EPS without NRI Growth Rate was -6.90% per year. The lowest was -61.90% per year. And the median was -15.80% per year.

Lukas Biomedical  (ROCO:6814) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Lukas Biomedical EPS (Basic) Related Terms

Lukas Biomedical EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Lukas Biomedical's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lukas Biomedical EPS (Basic) Chart

Lukas Biomedical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -1.50 -1.35 -1.28 -2.38 -2.05

Lukas Biomedical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.88 -1.09 -1.29 -1.02 -1.03
ROCO:6814
65GF Score
Lukas Biomedical Inc ROCO:6814
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lukas Biomedical EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Lukas Biomedical's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-85.633-0)/41.874
=-2.05

Lukas Biomedical's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-43.124-0)/41.874
=-1.03

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-2.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of NT$-2.05 mean?
Lukas Biomedical (ROCO:6814) has a EPS (Basic) of NT$-2.05 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lukas Biomedical and its competitors.
Is Lukas Biomedical's EPS (Basic) too high?
Lukas Biomedical's current EPS (Basic) is NT$-2.05. Overall, Lukas Biomedical has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's EPS (Basic) compare to VRTX and REGN?
Lukas Biomedical's EPS (Basic) of NT$-2.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Lukas Biomedical and its competitors. Lukas Biomedical's current EPS (Basic) is NT$-2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$21.85, compared to a current price of NT$25.60 — trading 17.2% above its estimated fair value. The current EPS (Basic) is NT$-2.05. Lukas Biomedical's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current EPS (Basic) is NT$-2.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?

Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued. The current stock price of NT$25.60 is trading 17.2% above its estimated GF Value™ of NT$21.85. GuruFocus considers Lukas Biomedical to be Modestly Overvalued.

Key valuation signals for ROCO:6814:

  • EPS (Basic): NT$-2.05
  • GF Value™: NT$21.85 vs. price of NT$25.60 (17.2% above fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lukas Biomedical Business Description

Address No. 14-16, Zhongxiao Road, 1st Floor, Banqiao District, New Taipei City, TWN, 220
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
65GF Score

Get the complete analysis for ROCO:6814

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$25.60
Price
NT$21.85
GF Value